WuXi Biologics WuXi AppTec is expected to provide world-class integrated biopharmace
WuXi Biologics is a subsidiary of the WuXi AppTec Group with branches in Wuxi, Shanghai and Suzhou. As a platform for innovative companies to realize their dream of developing new drugs, WuXi AppTec is expected to provide world-class integrated biopharmaceutical R&D and manufacturing services to more innovative biotech companies at home and abroad in the future, accelerating the process of bringing innovative biopharmaceuticals to market in China for the benefit of patients.
ResearchTechnology, Healthcare, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
15 Companies to Watch in September 2022- Healthcare
Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in September 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the startups operate.
Sep 30, 2022 12:32 PM
Ubrigene Bags Hundreds of Mns of CNY in Series C Financing Round
Ubrigene, dedicated to providing one-stop CDMO services for cell and gene therapies, will continue to improve its management system and incubate more specialized technology platforms with the fresh proceeds.
Sep 27, 2022 06:35 PM